Am J Ind Med

1. ALEXANDER BH, Ryan A, Church TR, Kim H, et al
   Mortality and cancer incidence in perfluorooctanesulfonyl fluoride production workers.
   Am J Ind Med. 2024;67:321-333.
   

   >> Share

   
   

   
   Am J Surg Pathol

2. KITAHAMA K, Shigematsu Y, Amori G, Sugawara E, et al
   RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma of the Bladder.
   Am J Surg Pathol. 2024;48:458-464.
   

   >> Share

   
   

   
   Anal Chem

3. WANG P, Wei X, Shen L, Xu K, et al
   Amplification-Free Analysis of Bladder Cancer MicroRNAs on Wrinkled Silica Nanoparticles with DNA-Functionalized Quantum Dots.
   Anal Chem. 2024 Mar 13. doi: 10.1021/acs.analchem.3c05204.
   

   >> Share

   
   

   
   Anesthesiology

4. ENLUND M, Hallberg H, Berglund A, Sherif A, et al
   Long-term survival after volatile or propofol general anesthesia for bladder cancer surgery: a retrospective national registry cohort study.
   Anesthesiology. 2024 Mar 11. doi: 10.1097/ALN.0000000000004969.
   

   >> Share

   
   

   
   Asian J Surg

5. KOU Z, Wang P, Jia D, Zhu H, et al
   Clinical analysis of small-cell carcinoma of the urinary bladder: A case report and review of literature.
   Asian J Surg. 2024;47:1602-1603.
   

   >> Share

   
   

   
   Biochem Pharmacol

6. XIE L, Liang S, Jiwa H, Zhang L, et al
   Securinine inhibits the tumor growth of human bladder cancer cells by suppressing Wnt/beta-catenin signaling pathway and activating p38 and JNK signaling pathways.
   Biochem Pharmacol. 2024 Mar 12:116125. doi: 10.1016/j.bcp.2024.116125.
   

   >> Share

   
   
7. LI L, Fu S, Wang J, Lu J, et al
   SRT1720 inhibits bladder cancer cell progression by impairing autophagic flux.
   Biochem Pharmacol. 2024;222:116111.
   

   >> Share

   
   

   
   Biol Direct

8. CHENG S, Li C, Liu L, Liu X, et al
   Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma.
   Biol Direct. 2024;19:20.
   

   >> Share

   
   

   
   BJU Int

9. VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
   The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
   BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
   

   >> Share

   
   
10. HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
    The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
    

    >> Share

    
    

    
    BJUI Compass

11. SHAH S, Ince J, Kockelbergh R
    Patient experience of bladder cancer: A data linkage study.
    BJUI Compass. 2024;5:382-388.
    

    >> Share

    
    

    
    BMC Cancer

12. LI X, Liang Z, Pan J, Zhang M, et al
    Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.
    BMC Cancer. 2024;24:328.
    

    >> Share

    
    

    
    BMC Urol

13. WANG R, Xu F, Yang Z, Cao J, et al
    The mechanism of PFK-1 in the occurrence and development of bladder cancer by regulating ZEB1 lactylation.
    BMC Urol. 2024;24:59.
    

    >> Share

    
    
14. SUN H, Gao F, Liu Y, Shao J, et al
    Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis.
    BMC Urol. 2024;24:57.
    

    >> Share

    
    

    
    BMJ Open

15. GUO L, Liu L, Liu Y, Yang T, et al
    Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
    BMJ Open. 2024;14:e080092.
    

    >> Share

    
    

    
    Can Urol Assoc J

16. FLURY-SUTTER S, Heuzeroth F, Arbelaez E, Bubendorf L, et al
    Efficacy and tolerability of bacillus Calmette-Guerin strain Russia for the treatment of non-muscle-invasive bladder cancer: Analysis of a prospective registry.
    Can Urol Assoc J. 2024 Mar 1. doi: 10.5489/cuaj.8552.
    

    >> Share

    
    

    
    Cancer Cell

17. WOLF B, Jain RK
    Unraveling a hidden player in lymphovascular invasion in bladder cancer.
    Cancer Cell. 2024 Mar 6:S1535-6108(24)00051-5. doi: 10.1016/j.ccell.2024.
    

    >> Share

    
    

    
    Cancer Commun (Lond)

18. TONG Z, Zhao Y, Bai S, Ebner B, et al
    The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer.
    Cancer Commun (Lond). 2024 Mar 11. doi: 10.1002/cac2.12532.
    

    >> Share

    
    

    
    Cancer Lett

19. LIN H, Fu L, Zhou X, Yu A, et al
    LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.
    Cancer Lett. 2024 Mar 8:216807. doi: 10.1016/j.canlet.2024.216807.
    

    >> Share

    
    

    
    Cancer Med

20. WANG P, Ning J, Chen W, Zou F, et al
    Comprehensive analysis indicated that NDE1 is a potential biomarker for pan-cancer and promotes bladder cancer progression.
    Cancer Med. 2024;13:e6931.
    

    >> Share

    
    

    
    Cancers (Basel)

21. DU C, Waltzer WC, Wilusz JE, Spaliviero M, et al
    Circular STAG2 RNA Modulates Bladder Cancer Progression via miR-145-5p/TAGLN2 and Is Considered as a Biomarker for Recurrence.
    Cancers (Basel). 2024;16:978.
    

    >> Share

    
    
22. STANKOWSKA W, Sarkisyan D, Bruhn-Olszewska B, Duzowska K, et al
    Tumor Predisposing Post-Zygotic Chromosomal Alterations in Bladder Cancer-Insights from Histologically Normal Urothelium.
    Cancers (Basel). 2024;16:961.
    

    >> Share

    
    
23. CHANG PH, Chen HY, Chang YS, Su PJ, et al
    Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy.
    Cancers (Basel). 2024;16:894.
    

    >> Share

    
    

    
    Cell Biosci

24. ZHUANG J, Zhang L, Zhang S, Zhang Z, et al
    Membrane-associated RING-CH 7 inhibits stem-like capacities of bladder cancer cells by interacting with nucleotide-binding oligomerization domain containing 1.
    Cell Biosci. 2024;14:32.
    

    >> Share

    
    

    
    Cell Death Dis

25. ZHANG L, Shi X, Zhang L, Mi Y, et al
    A first-in-class TIMM44 blocker inhibits bladder cancer cell growth.
    Cell Death Dis. 2024;15:204.
    

    >> Share

    
    

    
    Cell Signal

26. YANG W, Liu Z, Liu T
    Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
    Cell Signal. 2024;117:111107.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

27. FERRO M, Chiujdea S, Vartolomei MD, Bove P, et al
    Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2024;22:27-37.
    

    >> Share

    
    
28. MEAGHER M, Morgan KM, Deshler L, Puri D, et al
    The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study.
    Clin Genitourin Cancer. 2024 Feb 15:102055. doi: 10.1016/j.clgc.2024.
    

    >> Share

    
    
29. CAMPBELL RA, Khanna A, Boorjian SA, Knorr J, et al
    Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy.
    Clin Genitourin Cancer. 2024;22:157-163.
    

    >> Share

    
    
30. STANGL FP, Buehler OD, Wuethrich PY, Furrer MA, et al
    Sex Does Not Affect Survival: A Propensity Score-Matched Comparison in a Homogenous Contemporary Radical Cystectomy Cohort.
    Clin Genitourin Cancer. 2024;22:171-180.
    

    >> Share

    
    
31. NIZAM A, Rader RK, Tzeng A, Wei W, et al
    Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
    Clin Genitourin Cancer. 2024;22:368-379.
    

    >> Share

    
    
32. JAGANMURUGAN R, Arora A, Chandankhede U, Prakash G, et al
    Prognostic Significance of Lymph Node Density in Pathological Node Positive Urothelial Carcinoma of the Bladder -Upfront Surgery and Post Neoadjuvant Chemotherapy Cohorts.
    Clin Genitourin Cancer. 2024;22:385-393.
    

    >> Share

    
    
33. LYNCH C, Sweis RF, Modi P, Agarwal PK, et al
    Bladder-Preserving Trimodality Therapy With Capecitabine.
    Clin Genitourin Cancer. 2024;22:476-482.
    

    >> Share

    
    
34. SOARES A, Bourlon MT, Wong A, Joshi A, et al
    Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion.
    Clin Genitourin Cancer. 2024;22:467-475.
    

    >> Share

    
    
35. VON DEIMLING M, Rink M, Klemm J, Koelker M, et al
    Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-Term Survival Outcomes After Radical Cystectomy.
    Clin Genitourin Cancer. 2024;22:336-346.
    

    >> Share

    
    
36. TREPANIER G, Nykopp T, Rosebush-Mercier R, Gris T, et al
    Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guerin.
    Clin Genitourin Cancer. 2024;22:354-359.
    

    >> Share

    
    
37. KOHADA Y, Goto K, Tasaka R, Nishida K, et al
    Prognostic Impact of the Modified 5-Item Frailty Index After Radical Nephroureterectomy in Patients With Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study.
    Clin Genitourin Cancer. 2024;22:322-329.
    

    >> Share

    
    
38. FENOR DE LA MAZA MD, Villacampa G, Minana B, Barbas Bernardos G, et al
    First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies.
    Clin Genitourin Cancer. 2024;22:330-335.
    

    >> Share

    
    
39. SHIPP C, Jindal T, Chou J, Friedlander TW, et al
    Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.
    Clin Genitourin Cancer. 2024;22:315-321.
    

    >> Share

    
    

    
    Clin Transl Oncol

40. LUO C, Luo S, Wusimanjiang W, Wang Z, et al
    Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.
    Clin Transl Oncol. 2024 Mar 12. doi: 10.1007/s12094-024-03400.
    

    >> Share

    
    

    
    Cutan Ocul Toxicol

41. GUO Q, Jin L, Zhang T, Gao R, et al
    Literature analysis of cutaneous adverse reactions induced by tislelizumab.
    Cutan Ocul Toxicol. 2024;43:52-57.
    

    >> Share

    
    

    
    Diagnostics (Basel)

42. JIANG YH, Liu YS, Wei YC, Jhang JF, et al
    Hypermethylation Loci of ZNF671, IRF8, and OTX1 as Potential Urine-Based Predictive Biomarkers for Bladder Cancer.
    Diagnostics (Basel). 2024;14:468.
    

    >> Share

    
    

    
    Environ Mol Mutagen

43. WONG JYY, Fischer AH, Baris D, Beane Freeman LE, et al
    Urinary mutagenicity and bladder cancer risk in northern New England.
    Environ Mol Mutagen. 2024 Mar 11. doi: 10.1002/em.22588.
    

    >> Share

    
    

    
    Eur J Med Chem

44. OTVAGIN VF, Krylova LV, Peskova NN, Kuzmina NS, et al
    A first-in-class beta-glucuronidase responsive conjugate for selective dual targeted and photodynamic therapy of bladder cancer.
    Eur J Med Chem. 2024;269:116283.
    

    >> Share

    
    

    
    Eur Urol

45. CAVILLON A, Pouessel D, Houede N, Mathevet F, et al
    Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
    Eur Urol. 2024;85:293-300.
    

    >> Share

    
    
46. GUPTA S, Necchi A
    LEAP-011 in Urothelial Cancer. Unraveling the Puzzle: Combination or Cohort?
    Eur Urol. 2024;85:239-241.
    

    >> Share

    
    
47. HUELSTER HL, Gould B, Schiftan EA, Camperlengo L, et al
    Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
    Eur Urol. 2024;85:283-292.
    

    >> Share

    
    
48. MATSUBARA N, de Wit R, Balar AV, Siefker-Radtke AO, et al
    Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
    Eur Urol. 2024;85:229-238.
    

    >> Share

    
    
49. HEER R, Tan WS, Gravestock P, Vadiveloo T, et al
    Reply to Arnulf Stenzl, Morgan Roupret, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193-4.
    Eur Urol. 2024;85:309-312.
    

    >> Share

    
    

    
    Eur Urol Focus

50. ARITA Y, Kwee TC, Woo S, Shigeta K, et al
    Biparametric versus Multiparametric Magnetic Resonance Imaging for Assessing Muscle Invasion in Bladder Urothelial Carcinoma with Variant Histology Using the Vesical Imaging-Reporting and Data System.
    Eur Urol Focus. 2024;10:131-138.
    

    >> Share

    
    
51. SARI MOTLAGH R, Ghoreifi A, Yanagisawa T, Kawada T, et al
    Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following Radical Cystectomy: Two Systematic Reviews and Meta-analyses of Interplay Between Radical Cystectomy and Ren
    Eur Urol Focus. 2024;10:169-181.
    

    >> Share

    
    

    
    Front Genet

52. YIN JJ, Song YL, Guo YF, Dai YH, et al
    Transcriptome-wide 1-methyladenosine functional profiling of messenger RNA and long non-coding RNA in bladder cancer.
    Front Genet. 2024;15:1333931.
    

    >> Share

    
    

    
    Front Oncol

53. SEGATTO NV, Simoes LD, Bender CB, Sousa FS, et al
    Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro.
    Front Oncol. 2024;14:1323422.
    

    >> Share

    
    
54. LI F, Wang P, Ye J, Xie G, et al
    Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis.
    Front Oncol. 2024;14:1303918.
    

    >> Share

    
    
55. FENG S, Zhou D, Li Y, Yuan R, et al
    Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram.
    Front Oncol. 2024;14:1276526.
    

    >> Share

    
    

    
    Funct Integr Genomics

56. FAN L, Wang J, Zhang Z, Zuo Z, et al
    Identification of RNA methylation-related lncRNAs for prognostic assessment and immunotherapy in bladder cancer-based on single cell/Bulk RNA sequencing data.
    Funct Integr Genomics. 2024;24:56.
    

    >> Share

    
    

    
    Future Oncol

57. HOIMES CJ, Flaig TW, Milowsky MI, Friedlander TW, et al
    A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
    Future Oncol. 2024;20:351-360.
    

    >> Share

    
    

    
    Histopathology

58. YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
    Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en-bloc transurethral resection.
    Histopathology. 2024 Mar 13. doi: 10.1111/his.15177.
    

    >> Share

    
    

    
    Int J Cancer

59. ATALLAH A, Grossman A, Nauman RW, Pare JF, et al
    Systemic versus localized Bacillus Calmette Guerin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Int J Cancer. 2024 Mar 14. doi: 10.1002/ijc.34897.
    

    >> Share

    
    

    
    Int J Med Sci

60. YANG K, Qi ZX, Sun MX, Xie LP, et al
    Hyperoside induces cell cycle arrest and suppresses tumorigenesis in bladder cancer through the interaction of EGFR-Ras and Fas signaling pathways.
    Int J Med Sci. 2024;21:690-702.
    

    >> Share

    
    

    
    Int J Urol

61. ISHIKAWA Y, Tanaka H, Fujiwara M, Nakamura Y, et al
    Incidence and predictors of intraoperative hypotension during transurethral bladder tumor resection with oral 5-aminolevulinic acid.
    Int J Urol. 2024;31:238-244.
    

    >> Share

    
    
62. MORI K, Hatakeyama S, Enokida H, Miyake H, et al
    Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
    Int J Urol. 2024;31:194-207.
    

    >> Share

    
    
63. MATSUKAWA A, Morizane S, Shimizu R, Teraoka S, et al
    Chronic kidney disease and Charlson comorbidity index predict complications after robot-assisted radical cystectomy: A single-center study in Japan.
    Int J Urol. 2024;31:231-237.
    

    >> Share

    
    

    
    Int Urol Nephrol

64. JAKUS D, Solic I, Borovac JA, Situm M, et al
    The influence of the initial clinical presentation of upper tract urothelial carcinoma on histopathological tumor features.
    Int Urol Nephrol. 2024;56:1335-1341.
    

    >> Share

    
    
65. LI B, Lin Y, Yang Y, Wang Z, et al
    Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
    Int Urol Nephrol. 2024;56:1243-1251.
    

    >> Share

    
    

    
    Int Wound J

66. LI Q, Zhuo L, Zhang T
    Shame in patients undergoing ureterostomy: A cross-sectional survey.
    Int Wound J. 2024;21:e14793.
    

    >> Share

    
    

    
    J Am Soc Cytopathol

67. JIA L, Rood T, Kirkpatrick J, Sarode V, et al
    Utility of The Paris System (TPS) for upper urinary tract cytopathology: correlation with histology follow-up and UroVysion fluorescence in situ hybridization (FISH) analysis.
    J Am Soc Cytopathol. 2024;13:149-155.
    

    >> Share

    
    

    
    J Ethnopharmacol

68. WANG J, Xiao B, Ren S, Zeng D, et al
    A systematic review and meta-analysis of the anti-tumor effects of Paeoniae Radix Rubra in animal models.
    J Ethnopharmacol. 2024;326:117987.
    

    >> Share

    
    

    
    J Magn Reson Imaging

69. CAI L, Yu R, Liu P, Zhuang J, et al
    A Nomogram of MRI Features to Assess Muscle Invasion in VI-RADS 2 Tumors With Stalk.
    J Magn Reson Imaging. 2023 Aug 21. doi: 10.1002/jmri.28924.
    

    >> Share

    
    
70. TAKEUCHI M
    Editorial for "A Nomogram of MRI Features to Assess Muscle Invasion in VI-RADS 2 Tumors With Stalk".
    J Magn Reson Imaging. 2023 Aug 9. doi: 10.1002/jmri.28922.
    

    >> Share

    
    

    
    J Urol

71. ALLORY Y, Culine S, Krucker C, Fontugne J, et al
    Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
    J Urol. 2024;211:564-574.
    

    >> Share

    
    

    
    J Vet Intern Med

72. MCKENNA C, Poirier VJ, Oblak ML, Nykamp S, et al
    Reason for euthanasia in dogs with urothelial carcinoma treated with chemotherapy or radiation therapy or both: A retrospective observational study.
    J Vet Intern Med. 2024;38:1127-1134.
    

    >> Share

    
    

    
    J Wound Care

73. SUSKI M
    Reconstruction of a large scalp defect secondary to a rare cutaneous metastasis from urothelial bladder carcinoma using intact fish skin xenografts.
    J Wound Care. 2024;33.
    

    >> Share

    
    

    
    Jpn J Clin Oncol

74. TAGUCHI S, Kawai T, Nakagawa T, Kume H, et al
    Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review.
    Jpn J Clin Oncol. 2024;54:254-264.
    

    >> Share

    
    
75. MIYAKE M, Nishimura N, Oda Y, Miyamoto T, et al
    Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
    Jpn J Clin Oncol. 2024;54:329-338.
    

    >> Share

    
    

    
    Kaohsiung J Med Sci

76. LIANG PI, Wei YC, Chen HD, Ma YC, et al
    TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma.
    Kaohsiung J Med Sci. 2024;40:269-279.
    

    >> Share

    
    

    
    Kyobu Geka

77. HAGA N, Hashimoto S, Morimoto M
    [Multiple Pulmonary Metastases Seven Years After Transurethral Bladder Tumor Resection for Non-muscle Invasion Bladder Cancer:Report of a Case].
    Kyobu Geka. 2024;77:155-159.
    

    >> Share

    
    

    
    Med

78. MITTAL K, Joshi M
    FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape.
    Med. 2024;5:176-178.
    

    >> Share

    
    

    
    Medicine (Baltimore)

79. 
    A prognostic risk prediction model based on ferroptosis-related long non-coding RNAs in bladder cancer: A bulk RNA-seq research and scRNA-seq validation: Erratum.
    Medicine (Baltimore). 2024;103:e37547.
    

    >> Share

    
    
80. WANG W, Chen Y, Gu J
    Effectiveness of integrated nursing interventions in enhancing patient outcomes during postoperative intravesical instillation for non-muscle invasive bladder cancer: A comparative study.
    Medicine (Baltimore). 2024;103:e36871.
    

    >> Share

    
    
81. LI S, Wang J, Zhang Z, Wu Y, et al
    Establishment and validation of nomograms to predict the overall survival and cancer-specific survival for non-metastatic bladder cancer patients: A large population-based cohort study and external validation.
    Medicine (Baltimore). 2024;103:e37492.
    

    >> Share

    
    

    
    Mol Cancer

82. SHI X, Pang S, Zhou J, Yan G, et al
    Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs.
    Mol Cancer. 2024;23:52.
    

    >> Share

    
    

    
    Mol Pharm

83. ZHANG Y, Jia R, Wang X, Zhang Y, et al
    Targeted Delivery of Catalase and Photosensitizer Ce6 by a Tumor-Specific Aptamer Is Effective against Bladder Cancer In Vivo.
    Mol Pharm. 2024 Mar 11. doi: 10.1021/acs.molpharmaceut.3c01047.
    

    >> Share

    
    

    
    Nutrients

84. XIE H, Rutz J, Maxeiner S, Grein T, et al
    Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro.
    Nutrients. 2024;16:623.
    

    >> Share

    
    

    
    Pathologica

85. BRUNELLI M, Gobbo S, Malpeli G, Sirgiovanni G, et al
    TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma.
    Pathologica. 2024;116:55-61.
    

    >> Share

    
    

    
    Transl Androl Urol

86. LAN T, Ran S, Gao M, Li W, et al
    A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend?
    Transl Androl Urol. 2024;13:293-307.
    

    >> Share

    
    
87. JALALIZADEH M, Reis LO
    Understanding bladder cancer by genome-wide association studies.
    Transl Androl Urol. 2024;13:363-365.
    

    >> Share

    
    
88. MENG W, Li N, Chen B, Zhang H, et al
    Reliable prognostic definition and immunotherapy response prediction in bladder cancer, based on a novel aging-associated 5-gene signature model.
    Transl Androl Urol. 2024;13:193-208.
    

    >> Share

    
    

    
    Transl Cancer Res

89. LI H, Bao X, Xiao Y, Yin H, et al
    Identification and verification of anoikis-related gene markers to predict the prognosis of patients with bladder cancer and assist in the diagnosis and treatment of bladder cancer.
    Transl Cancer Res. 2024;13:579-593.
    

    >> Share

    
    

    
    Urol J

90. NAGAYAMA J, Yamamoto A, Naito Y, Kamikawa H, et al
    Efficacy of the Addition of Robot-assisted Radical Cystectomy with Extracorporeal Urinary Diversion after an Enhanced Recovery Protocol.
    Urol J. 2024;21:40-46.
    

    >> Share

    
    

    
    Urol Oncol

91. XU VE, Antar RM, Bertozzi L, Drouaud A, et al
    Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases.
    Urol Oncol. 2024 Mar 12:S1078-1439(24)00337.
    

    >> Share

    
    
92. REIKE MJ, de Jong JJ, Bismar TA, Boorjian SA, et al
    Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
    Urol Oncol. 2024 Mar 12:S1078-1439(24)00043.
    

    >> Share

    
    
93. WOLDU S, Lotan Y
    Reply to Khurshid R. Ghani's letter to editor regarding the article "Early experience with UGN-101 for the treatment of upper tract urothelial cancer: a multicenter evaluation of practice patterns and outcomes".
    Urol Oncol. 2024;42:36.
    

    >> Share

    
    
94. KATAYAMA S, Iwata T, Kawada T, Okamoto Y, et al
    Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Urol Oncol. 2024;42:70.
    

    >> Share

    
    
95. YE J, Wang X, Liao X, Chen Z, et al
    Survival impact of variant histology in patients with upper tract urothelial carcinoma after radical nephroureterectomy.
    Urol Oncol. 2024;42:69.
    

    >> Share

    
    

    
    Urology

96. HUELSTER HL, Mason NT, Davaro F, Naqvi SMH, et al
    Cost-Utility of Initial Management of High-grade T1 Bladder Cancer with Intravesical BCG vs Immediate Radical Cystectomy.
    Urology. 2024 Mar 9:S0090-4295(24)00126-2. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    

    
    World J Urol

97. PFISTER C, Harter V, Allory Y, Culine S, et al
    Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?
    World J Urol. 2024;42:140.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share